Los Angeles Convention Center
Los Angeles, CA
May 16-20, 2023

VGXI, Inc.  

We look forward to meeting with you at ASGCT 2023!

VGXI is a leading plasmid DNA contract manufacturer (CDMO) with over 20 years of experience providing high-quality cGMP products to clinical trials worldwide. Applications include DNA vaccines, immunotherapies, and cell and gene therapies.

The company's continuous, low-shear AIRMIX® lysis technology and optimized purification process provide highly supercoiled plasmid with exceptional purity across all manufacturing scales through commercial supply. VGXI's tenured team can also provide flexible solutions tailored to clients' challenging and/or unique project requirements.

Range of Services Provided:

  • Pre-clinical, Highly Documented (HD), and full cGMP plasmid DNA production to support pre-IND through clinical and commercial supply
  • Process Development and Optimization services, Cell Banking, QC release testing, and stability testing 
  • GMP Fill/Finish
  • Pre-clinical through GMP production of RNA products

Brands: VGXI provides pre-clinical through GMP manufacturing services for plasmid DNA and RNA products.

 Press Releases

  • With original operations based in The Woodlands, TX, industry-recognized plasmid DNA contract manufacturer VGXI, Inc. celebrated the official Grand Opening of its new headquarters and expanded manufacturing facility in Conroe, TX.

    VGXI Grand Opening and Ribbon Cutting

    VGXI, Inc., a specialized contract developer and manufacturer (CDMO) of nucleic acid biopharmaceuticals including gene therapies, DNA vaccines, and RNA medicines, celebrated the official grand opening of its new headquarters and manufacturing facility located at Deison Technology Park in Conroe, TX. U.S. Congressman Kevin Brady and the Consul General of the Republic of Korea in Houston Ahn Myung Soo attended the ribbon cutting on October 7, 2022 to recognize this important milestone and VGXI’s contributions to the global pharmaceutical community.

    The ribbon cutting was attended by VGXI clients, contractors, and business partners, as well as city of Conroe officials and representatives of the local and Texas biotechnology communities, including Ms. Ann Tanabe, CEO of BioHouston.

    “VGXI’s clients and collaborators are developing the next generation of gene therapies and vaccines,” said CEO Young Park. “This new VGXI headquarters is purpose-built to leverage the company’s existing expertise in DNA and RNA manufacturing and greatly expand our capacity to support growing industry demands.”

    VGXI has operated as a CDMO since 2003 supporting the development of new cancer therapies, gene and cell therapies, and DNA vaccines for critical emerging diseases including Ebola, MERS, Zika, and COVID-19. With expanded capabilities offered by the 120,000 square-foot Conroe facility, the company is now booking 2023 GMP manufacturing slots at fermentation scales from 10L to 1500L across multiple independent manufacturing trains. Dedicated areas are also available for personalized immunotherapy indications and GMP mRNA production.


    With over 20 years of experience VGXI, Inc. is a leading provider of plasmid DNA manufacturing and development services. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and highly experienced development team. VGXI, Inc. is a GeneOne company.


    GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) headquartered in Seoul, South Korea is an international biotechnology company and a leading contract manufacturer of DNA plasmids for use in vaccines, gene therapies, and cell therapies. GeneOne has recently expanded into the manufacture and development of mRNA. GeneOne has maintained a focus on vaccines against emerging infectious diseases to address global needs, including in resource challenged regions. Its small molecule portfolio of immunomodulators address diseases such as prevention of upper respiratory bacterial and viral diseases, and treatment of autoimmune and inflammatory diseases. GeneOne has three products against COVID-19 in clinical development: GLS-5310 DNA vaccine (Phase I/IIa), GLS-1200 nasal spray to prevent COVID-19 infection (Phase II), and GLS-1027 to prevent the inflammation and clinical worsening for those infected with COVID-19 (Phase II).

    For more information, visit https://www.genels.com.


    Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.


  • GMP Plasmid Manufacturing
    VGXI provides pre-clinical through GMP manufacturing services for small to large-scale and commercial plasmid DNA supply....

  • Services Provided:

    • GMP Cell Banking
    • Process and Assay Development
    • DNA production scales from 10L to 1500L fermentation
    • Manufacturing for pre-clinical through commercial supply
    • Rapid Turnaround service available for personalized applications
    • GMP fill/finish capabilities